Peptide Tolerance & Desensitisation: Why Peptides Stop Working and How to Prevent It

Tolerance — also called desensitisation or tachyphylaxis — is the phenomenon where the body's response to a peptide diminishes with repeated use. The same dose that produced a robust effect in week 1 may produce a noticeably weaker response by week 6.

This is a normal biological process. The body's cellular machinery is designed to maintain homeostasis. When a receptor is continuously stimulated, cells adapt to restore balance.

Tolerance is NOT: - Degradation — the peptide hasn't broken down (assuming proper storage) - Placebo wearing off — tolerance involves measurable biological changes - Reaching a plateau — some benefits stabilise at a new set point rather than the peptide losing effectiveness

How common is it? Some degree of tolerance occurs with most peptides that modulate hormonal or receptor-mediated pathways. However, the rate and severity vary dramatically. GHRP-6 shows rapid tolerance within weeks; semaglutide maintains efficacy for years.

Several cellular mechanisms contribute to tolerance:

1. Receptor internalisation (downregulation): When repeatedly activated, cells pull receptors from the surface into vesicles. Fewer surface receptors = fewer binding sites. Can occur within hours to days. Usually reversible within days to weeks. Most affects GHRP receptors.

2. Receptor uncoupling: The receptor remains on the surface but its intracellular signalling connection is disrupted. The peptide binds but the signal isn't transmitted. Takes days to weeks. Reversible with cessation.

3. Downstream signal adaptation: Even if the receptor works normally, downstream molecules adapt to reduce signal strength. Takes weeks to months. Slower to reverse.

4. Increased degradation: The body upregulates enzymes that break down the peptide, reducing effective concentration. Takes weeks. Reversible.

5. Counter-regulatory responses: The body activates opposing systems. For GH secretagogues, increased somatostatin inhibits GH release. Takes days to weeks. Usually rapid reversal.

HIGH tolerance risk — GHRPs:

GHRP-6 and GHRP-2: Most susceptible. GH response can diminish 30–50% within 2–4 weeks. The ghrelin receptor is particularly prone to internalisation. Cycling essential.

Hexarelin: Similar or faster desensitisation. Less commonly used partly because of tolerance issues.

MODERATE risk — GHRH Analogues:

CJC-1295 (no DAC), Sermorelin: GHRH receptors desensitise more slowly. Meaningful tolerance after 8–12 weeks. GH response may reduce 20–30%. Standard cycling maintains efficacy.

Ipamorelin: Despite acting on the ghrelin receptor, shows slower tolerance than GHRP-6 — possibly due to selective receptor activation. Some researchers report sustained effects over 12+ weeks. Cycling still recommended.

LOW risk — GLP-1 Agonists:

Semaglutide, Tirzepatide: Remarkably resistant to clinically significant tolerance. Sustained efficacy over 68–104 weeks in trials. Some plateau likely reflects new metabolic equilibrium, not desensitisation. No cycling needed.

MINIMAL risk — Healing Peptides:

BPC-157, TB-500: Used for defined periods aligned with recovery timelines. Limited desensitisation evidence during typical 4–8 week use.

VARIABLE — Neuropeptides:

Semax, Selank: Moderate tolerance potential beyond 3–4 weeks. Individual variation significant. 2–4 week cycles recommended.

GH secretagogues: - Sleep quality decline — often the first benefit to appear and first to fade - Recovery speed plateaus mid-cycle - Skin quality improvements stop progressing - Objective measure: IGF-1 levels plateau or decline mid-cycle despite consistent dosing

Neuropeptides: - Reduced subjective enhancement — the cognitive "edge" becomes less noticeable - Wanting to increase dose to achieve the same effect — classic tolerance indicator - Can't distinguish "on" days from "off" days

GLP-1 agonists (usually plateau, not true tolerance): - Weight loss stalling — usually metabolic adaptation at lower body weight - Appetite returning — may indicate some adaptation, usually responds to dose adjustment - GI side effects resolving — desirable tolerance to side effects while efficacy continues

Tracking recommendations: Keep a simple log recording sleep quality (1–10), recovery (1–10), energy/cognition, measurable metrics, and blood work at baseline, week 6, and week 12.

1. Structured cycling (most important) - GH secretagogues: 8–12 weeks on, 4 weeks off - Neuropeptides: 2–4 weeks on, 2–4 weeks off - Mini-cycling: 5 days on / 2 days off for extended protocols

2. Dose modulation - Dose ramping: Start low, increase, reduce toward end of cycle - Pulsatile dosing: Full dose Mon/Wed/Fri, half dose Tue/Thu - Limited clinical evidence but theoretical pharmacological support

3. Pathway rotation For GH secretagogues, rotate receptor pathways: - Cycle 1: Ipamorelin (ghrelin pathway) - Cycle 2: CJC-1295 no DAC (GHRH pathway) - Cycle 3: Stack both - Each pathway gets longer rest while GH stimulation continues

4. Sensitisation support - Sleep: 7–9 hours supports receptor recycling - Exercise: Resistance training may upregulate GH receptor sensitivity - Fasting: Intermittent fasting enhances GH pulse amplitude - Stress management: Chronic cortisol interferes with receptor signalling

5. Avoid premature dose escalation Higher doses accelerate downregulation. If effects diminish, a break is almost always better than a dose increase.

An important distinction often confused:

Tolerance = the peptide is genuinely less effective. Receptors have adapted. Same dose → weaker signal.

New baseline = you've reached a new physiological equilibrium. The peptide is still working; there's simply less room for improvement.

Example — new baseline (not tolerance): - Week 1: IGF-1 150 → start Ipamorelin → sleep improves dramatically - Week 4: IGF-1 250 → sleep consistently good → body comp improving - Week 8: IGF-1 260 → sleep still good → body comp stable at new level - The peptide is maintaining IGF-1 at 260. Improvements have stabilised.

True tolerance: - Week 1: IGF-1 150 → start Ipamorelin - Week 4: IGF-1 250 — good response - Week 8: IGF-1 200 — declining despite consistent dosing - Week 12: IGF-1 170 — approaching pre-treatment levels - The GH response is diminishing. Washout needed.

The test: Take a 2-week break, then resume. If the initial robust response returns → tolerance (break helped). If response is similar to pre-break → new baseline (peptide was working throughout).

Can you become permanently desensitised? Extremely unlikely with standard protocols. Receptor populations recover after stimulus removal. Even GHRP receptors fully recover within 2–4 weeks.

Does tolerance mean the peptide stopped working completely? Usually not. Tolerance is typically partial — a 40% response versus the initial 100%. But diminished response may not justify continued cost and effort.

Is tolerance dose-dependent? Generally yes. Higher doses → faster, more pronounced desensitisation. Use minimum effective dose.

Can combining peptides affect tolerance? Yes — stacking different-pathway peptides means each receptor system receives less continuous stimulation, potentially slowing tolerance for each.

Should I increase the dose when tolerance develops? No. This accelerates receptor downregulation, creating an escalation cycle. A planned break is almost always better.

Is peptide tolerance like drug addiction? No. Peptide tolerance is a receptor-level phenomenon — reduced cellular responsiveness. Research peptides do not produce addiction, dependence, or withdrawal. GLP-1 agonist discontinuation causes physiological rebound (appetite/weight), not addiction.

Disclaimer: This article is for educational purposes only. It is not medical advice. Individual responses to peptides vary. Always consult a healthcare professional for guidance on peptide research protocols.